Advances in intracerebral hemorrhage management

Stroke

Volumn 37, Issue 2, 2006, Pages 301-304

  Juvela, Seppo ^a   Kase, Carlos S ^b,c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Intracerebral hemorrhage

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; GLUTAMIC ACID; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; MATRIX METALLOPROTEINASE; MOLECULAR MARKER; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; WARFARIN; BLOOD CLOTTING FACTOR 7A; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT PROTEIN;

BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INJURY; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG USE; HEMATOMA; HUMAN; NEUROSURGERY; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; THROMBOSIS; BLOOD; INTERNAL MEDICINE; METHODOLOGY; REVIEW; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ASPIRIN; CEREBRAL HEMORRHAGE; CLINICAL TRIALS; FACTOR VIIA; HUMANS; INTERNAL MEDICINE; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 33644857324     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000200445.68303.25     Document Type: Short Survey

References (38)

1. Qureshi AI, Safdar K, Weil EJ, Barch C, Bliwise DL, Colohan AR, Mackay B, Frankel MR. Predictors of early deterioration and mortality in black Americans with spontaneous intracerebral hemorrhage. Stroke. 1995;26:1764-1767.
2. Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, Spilker J, Duldner J, Khoury J. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28:1-5.
3. Mayer SA, Sacco RL, Shi T, Mohr JP. Neurologic deterioration in noncomatose patients with supratentorial intracerebral hemorrhage. Neurology. 1994;44:1379-1384.
4. Suzuki R, Ohno K, Hiratsuka H, Inaba Y. Chronological changes in brain edema in hypertensive intracerebral hemorrhage observed by CT and xenon-enhanced CT. In: Inaba Y, Klatzo I, Spatz M, eds. Brain Edema. Berlin: Springer; 1985, 613-620.
5. Xi G, Keep RF, Hoff JT. Pathophysiology of brain edema formation. Neurosurg Clin N Am. 2002;13:371-383.
6. Lee KR, Colon GP, Betz AL, Keep RF, Kim S, Hoff JT. Edema from intracerebral hemorrhage: the role of thrombin. J Neurosurg. 1996;84: 91-96.
7. Hamada R, Matsuoka H Antithrombin therapy for intracerebral hemorrhage. Stroke. 2000;31:791 (letter).
8. Bar-Shavit R, Benezra M, Sabbah V, Bode W, Vlodavsky I. Thrombin as a multifunctional protein: induction of cell adhesion and proliferation. Am J Respir Cell Mol Biol. 1992;6:123-130.
9. Malik AB, Fenton JW. Thrombin-mediated increase in vascular endothelium permeability. Semin Thromb Hemost. 1992;18:193-199.
10. Lee KR, Kawai N, Kim S, Sagher O, Hoff JT. Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model. J Neurosurg. 1997;86:272-278.
11. Castillo J, Dávalos A, Álvarez-Sabín J, Pumar JM, Leira R, Silva Y, Montaner J, Kase CS. Molecular signatures of brain injury after intracerebral hemorrhage. Neurology. 2002;58:624-629.
12. Romanic AM, Madri JA. Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol. 1994;4:145-156.
13. Alvarez-Sabín J, Delgado P, Abilleira S, Molina CA, Arenillas J, Ribó M, Santamarina E, Quintana M, Monasterio J, Montaner J. Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke. 2004;35:1316-1322.
14. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabín J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107:598-603.
15. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, Harrison DG, Tsao PS. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res. 2001;88:1291-1298.
16. Demchuk AM, Morgenstern LB, Krieger DW, Chi LT, Hu W, Wein TH, Hardy RJ, Grotta JC, Buchan AM. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999;30:34-39.
17. Bruno A, Levine SR, Frankel MR, Brott TG, Lin Y, Tilley BC, Lyden PD, Broderick JP, Kwiatkowski TG, Fineberg SE; NINDS rt-PA Stroke Study Group. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology. 2002;59:669-674.
18. Kase CS, Furlan AJ, Wechsler LR, Higashida RT, Rowley HA, Hart RG, Molinari GF, Frederick LS, Roberts HC, Gebel JM, Sila CA, Schulz GA, Roberts RS, Gent M, & the PROACT II Investigators. Symptomatic intracerebral hemorrhage after intra-arterial thrombolysis with prourokinase in acute ischemic stroke: The PROACT II trial. Neurology. 2001;57:1603-1610.
19. Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, Dávalos A. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke. 2004;35:1671-1676.
20. Broderick JP, Brott T, Tomsick T, Miller R, Huster G. Intracerebral hemorrhage more than twice as common as subarachnoid hemorrhage. J Neurosurg. 1993;78:188-191.
21. Ariesen MJ, Claus SP, Rinkel GJE, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke. 2003;34:2060-2065.
22. Juvela S, Hillbom M, Palomäki H. Risk factors for spontaneous intracerebral hemorrhage. Stroke. 1995;26:1558-1564.
23. Kurth T, Kase CS, Berger K, Schaeffner ES, Buring JE, Gaziano JM. Smoking and the risk of hemorrhagic stroke in men. Stroke. 2003;34:1151-1155.
24. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
25. Juvela S. Risk factors for impaired outcome after spontaneous intracerebral hemorrhage. Arch Neurol. 1995;52:1193-2000.
26. Saloheimo P, Ahonen M, Juvela S, Pyhtinen J, Savolainen E-R, Hillbom M. Regular aspirin use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke. 2006;37:129-133.
27. Toyoda K, Okada Y, Minematsu K, Kamouchi M, Fujimoto S, Ibayashi S, Inoue T. Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology. 2005;65:1000-1004.
28. McKissock W, Richardson A, Taylor J. Primary intracerebral haemorrhage. A controlled trial of surgical and conservative treatment in 180 unselected cases. Lancet. 1961;2:221-226.
29. Auer LM, Deinsberger W, Niederkorn K, Gell G, Kleinert R, Schneider G, Holzer P, Bone G, Mokry M, Korner E, Kleinert G, Hanusch S. Endoscopic surgery versus medical treatment for spontaneous intracerebral hematoma: a randomized study. J Neurosurg. 1989;70:530-535.
30. Juvela S, Heiskanen O, Poranen A, Valtonen S, Kuurne T, Kaste M, Troupp H. The treatment of spontaneous intracerebral hemorrhage: a prospective randomized trial of surgical and conservative treatment. J Neurosurg. 1989;70:755-758.
31. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MDM, Barer DH; for the STICH investigators. Early versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet. 2005;365:387-397.
32. Poungvarin N, Bhoopat W, Viriyavejakul A, Rodprasert P, Buranasiri P, Sukondhabhant S, Hensley MJ, Strom BL. Effects of dexamethasone in primary supratentorial intracerebral hemorrhage. N Engl J Med. 1987;316:1229-1233.
33. Yu YL, Kumana CR, Lauder IJ, Cheung YK, Chan FL, Kou M, Chang CM, Cheung RTF, Fong KY. Treatment of acute cerebral hemorrhage with intravenous glycerol: a double-blind, placebo-controlled, randomized trial. Stroke. 1992;23:967-971.
34. Italian Acute Stroke Study Group. Haemodilution in acute stroke: results of the Italian haemodilution trial. Lancet. 1988;1:318-321.
35. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T; for the Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-785.
36. Brown DL, Morgenstern LB. Stopping the bleeding in intracerebral hemorrhage. N Engl J Med. 2005;352:828-830 (editorial).
37. Qureshi AI, Bliwise DL, Bliwise NG, Akbar MS, Uzen G, Frankel MR. Rate of 24-hour blood pressure decline and mortality after spontaneous intracerebral hemorrhage: a retrospective analysis with a random effects regression model. Crit Care Med. 1999;27:480-485.
38. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542-547.